 Home > Medical News > Latest Medical News > BeiGene PD1 monoclonal antibody combined with DKK1 monoclonal antibody for first-line treatment of gastric cancer ORR reached 68.2%

BeiGene PD1 monoclonal antibody combined with DKK1 monoclonal antibody for first-line treatment of gastric cancer ORR reached 68.2%

 Last Update: 2021-09-18
 Source: Internet
 Author: User

Tags

effects low protein

used oil label

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Article source: Medical Rubik's Cube Info

Author: Sunshine

Recently, Leap Therapeutics announced that its DKK1 monoclonal antibody DKN-01 combined with BeiGene’s tislelizumab and chemotherapy (capecitabine, oxaliplatin) can be used in the treatment of gastric cancer or gastroesophageal junction cancer (G/ The ORR in the phase IIa clinical trial (DisTinGuish, NCT04363801) of patients in GEJ) reached 68.
2%
.

The complete data will be announced at the upcoming ESMO conference

DKN-01 is a humanized monoclonal antibody targeting Dickkopf-1 (DKK1) protein, developed by Leap
.

DKK1 can regulate the Wnt signaling pathway and is highly expressed in a variety of tumors, helping to maintain an immunosuppressive tumor microenvironment

Source: Leap official website

Currently, DKN-01 is undergoing clinical trials for gastroesophageal cancer, hepatobiliary cancer, gynecological cancer and prostate cancer
.

Source: Leap official website

In January 2020, BeiGene and Leap reached a partnership to obtain the exclusive option and licensing rights for clinical development and promotion of DKN-01 in Asia (except Japan), Australia and New Zealand, with a total transaction amount of US$135 million
.

DisTinGuish is a non-randomized, open-label, multi-center Phase IIa study, which will be conducted in two parts (A/B) at the same time.
Safety, tolerability and effectiveness in adult patients with advanced or metastatic G/GEJ
.

The study recruited 25 patients with gastroesophageal adenocarcinoma (GEA) who had not received systemic treatment, including 17 GEJ patients and 8 GC patients
.

The results showed that among the patients who received the complete treatment cycle of DKN-01, the ORR was 68.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.